Sandoz Group AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
An Efficacy and Safety Study With Integrated Pharmacokinetics (PK) and Pharmacodynamic (PD) Assessment to Compare the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3
Not yet recruiting
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Biological: CYB704Biological: Ocrevus-EUBiological: Ocrevus-US
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 518
- Registration Number
- NCT06847724
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Phase 3
Recruiting
- Conditions
- Melanoma
- Interventions
- Drug: JPB898 (Induction and Maintenance)Drug: Opdivo-EU (Induction)Drug: Opdivo-US (Induction)Drug: Yervoy-EU (Induction)Drug: Opdivo-EU (Maintenance)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06587451
- Locations
- 🇨🇳
Sandoz Investigational Site, Taoyuan City, Taiwan
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06159790
- Locations
- 🇻🇳
Sandoz Investigational Site, Hà Nội, Vietnam
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 318
- Registration Number
- NCT06153238
- Locations
- 🇹🇷
Sandoz Investigational Site, Ankara, Turkey
Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis
Phase 1
Terminated
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 38
- Registration Number
- NCT05887843
- Locations
- 🇨🇦
Sandoz Investigational Site, Toronto, Ontario, Canada
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Recruiting
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Other: Hyrimoz
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 562
- Registration Number
- NCT05633771
- Locations
- 🇧🇪
Sandoz Investigational Site Belgium, Bruxelles, Belgium
🇫🇷Sandoz Investigational Site France, Troyes, France
Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Combination Product: Momat Rhino AdvanceCombination Product: Azelastine + Mometazone, nasal spray
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 472
- Registration Number
- NCT05590598
- Locations
- 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation
Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections
Phase 3
Completed
- Conditions
- Acute Uncomplicated Respiratory Tract Infections
- Interventions
- Drug: Broncho-munal®Drug: Placebo
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 556
- Registration Number
- NCT05588804
- Locations
- 🇷🇺
Sandoz Investigative Site, Saint-Petersburg, Russian Federation
In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 12
- Registration Number
- NCT05429775
- Locations
- 🇬🇧
Sandoz Investigative Site, Nottingham, England, United Kingdom
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 669
- Registration Number
- NCT05311475
- Locations
- 🇵🇱
Sandoz Investigative Site, Wrocław, Poland
© Copyright 2025. All Rights Reserved by MedPath